arrow
G

Gerald W. Prager

medical university vienna
H指数:44
被引数:6,692

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Outcomes of Cisplatin, Gemcitabine, and Durvalumab According to TOPAZ-1 Study Eligibility: A Large Global Analysis in a Real-World Setting

根据TOPAZ-1研究入组标准评估顺铂、吉西他滨和度伐利尤单抗的疗效:一项真实世界环境下的全球性大规模分析

2026-08-160
PRE
Exploring the Role of Surgery After Systemic Therapy in Locally Advanced Biliary Tract Cancer: Outcomes From a Large Retrospective Multinational Real-World Cohort Treated With Cisplatin, Gemcitabine, and Durvalumab

探索系统性治疗后的手术治疗在局部晚期胆道癌中的作用:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的大型回顾性跨国真实世界队列的结局

2026-08-150
PRE
First-line treatment efficacy of anti-EGFR versus anti-VEGF antibodies in BRAFV600E-mutated metastatic colorectal cancer according to primary tumor sidedness: a pooled analysis of seven clinical trials performed in the first-line treatment of mCRC (German AIO Study Group)

抗EGFR抗体与抗VEGF抗体在BRAFV600E突变型转移性结直肠癌中根据原发肿瘤侧性的初始治疗疗效:一项在mCRC初始治疗中进行的七项临床试验的合并分析(德国AIO研究组)

2025-11-130
OAAI
Durvalumab in Advanced Biliary Tract Cancer: Real-World Data From a Large Cohort of Patients Across Multiple International Centers

度伐利尤单抗在晚期胆道癌中的应用:来自多个国际中心大型患者队列的真实世界数据

2025-11-120
OAAI
Clinical practice and implications of biomarker testing in biliary tract cancer: an observational study☆

胆道癌中生物标志物检测的临床实践与意义:一项观察性研究☆

2025-11-040
OAAI
Genomic Pathway Alterations and Their Prognostic Impact in Biliary Tract Cancer: Insights from a Multinational Cohort Treated with Cisplatin, Gemcitabine, and Durvalumab

基因组通路改变及其在胆道癌中的预后影响:来自接受顺铂、吉西他滨和度伐利尤单抗治疗的跨国队列的见解

2025-10-030
PRE
Prospective validation of the modified metastatic colorectal cancer score (mCCS) in >600 patients with RAS-wild-type metastatic colorectal cancer treated with first-line panitumumab plus FOLFIRI/FOLFOX: Final results of the non-interventional study VALIDATE

对接受一线帕尼单抗联合FOLFIRI/FOLFOX治疗且具有RAS野生型转移性结直肠癌的>600例患者,进行改良转移性结直肠癌评分(mCCS)的前瞻性验证:非干预性研究VALIDATE的最终结果

2025-09-090
OAAI
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population

接受顺铂、吉西他滨和度伐利尤单抗治疗的晚期胆道癌患者中分子改变的影响:一项大型、真实世界、全球性人群研究

2025-09-011
PRE
Lack of association between prior or concurrent malignancies and overall survival in gastroesophageal cancer: evidence from a large European single-center cohort

先前或并发恶性肿瘤与胃癌患者总生存期之间缺乏关联:来自一项大型欧洲单中心队列的证据

2025-08-290
OAAI
Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

两项3期研究的合并安全性分析,这些研究调查了转移性结直肠癌患者的氟尿苷/替匹拉西加贝伐单抗

2025-01-161
OAAI
Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT Trial

三氟尿idine/替匹嘧啶联合贝伐珠单抗治疗对难治性转移性结直肠癌患者健康相关生活质量及体能状态的影响:一项SUNLIGHT III期试验分析

2024-12-110
OAAI
Clinical Trial Data Review of the Combination FTD/TPI plus Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer

FTD/TPI联合贝伐单抗治疗不可切除转移性结直肠癌的临床试验数据回顾

2024-09-260
OAAI
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population

Durvalumab联合吉西他滨和顺铂治疗晚期胆道癌: 大量现实世界人口

2024-09-013
PRE
Immune cell distribution and DNA methylation signatures differ between tumor and stroma enriched compartment in pancreatic ductal adenocarcinoma
2024-09-011
OAAI